Acadia Pharmaceuticals

Acadia Pharmaceuticals
Public
Traded as NASDAQ: ACAD
Russell 2000 Component
Industry Biopharmaceutical, Healthcare
Founded 1993
Headquarters San Diego, CA, U.S.
Key people
 Stephen R. Davis
CEO
Products Pimavanserin
Revenue Increase $124.1M (2017)
Increase $22.85M (2011)
Increase $22.76M(2011)
Total assets Increase 108.71M (2012)
Number of employees
 400
Website http://www.acadia-pharm.com/

ACADIA Pharmaceuticals, Inc. is a biopharmaceutical company headquartered in San Diego, California[1]. On April 29, 2016, the FDA approved ACADIA’s drug, NUPLAZID, for the treatment of hallucinations and delusions associated with Parkinson’s disease psychosis[2]. NUPLAZID is the trade name for ACADIA’s proprietary molecule, pimavanserin, a selective serotonin inverse agonist preferentially targeting 5-HT2a receptors.

ACADIA is running multiple Phase 2 and Phase 3 trials with pimavanserin in several central nervous system conditions: dementia-related psychosis[3], major depressive disorder[4],schizophrenia inadequate response[5],and schizophrenia negative symptoms[6].

References

  1. ↑ "ACADIA Pharmaceuticals website".
  2. ↑ "FDA Press Release,". April 29, 2016.
  3. ↑ "Acadia Is Starting Phase 3 Trial of Nuplazid for Dementia-related Psychosis".
  4. ↑ "ACADIA Pharmaceuticals Initiates Phase III Trial of Pimavanserin for Adjunctive Treatment in Patients with Schizophrenia".
  5. ↑ "ACADIA Pharmaceuticals Initiates Phase III Trial of Pimavanserin for Adjunctive Treatment in Patients with Schizophrenia".
  6. ↑ "ACADIA Pharmaceuticals Initiates Phase II Trial of Pimavanserin for Adjunctive Treatment in Patients With Negative Symptoms of Schizophrenia".
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.